Status | Study |
Active, not recruiting |
Study Name: Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) Condition: Hodgkin Lymphoma Anaplastic Large Cell Lymphoma Date: 2012-08-02 Interventions: Drug: Brentuximab Vedotin Dose |
Recruiting |
Study Name: Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Condition: Recurrent Childhood Anaplastic Large Cell Lymphoma Recurrent Ne Date: 2012-05-24 Interventions: Drug: crizotinib Given orally |
Active, not recruiting |
Study Name: Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Condition: Relapsed or Refractory Hodgkin Lymphoma Relapsed or Refractory Anaplas Date: 2011-12-12 Interventions: Drug: Brentuximab vedotin Brentuximab vedotin IV infusion |
Completed |
Study Name: Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma Condition: Lymphoma Date: 2011-06-02 Interventions: Genetic: microarray analysis Genetic: prot |
Active, not recruiting |
Study Name: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms Condition: Lymphoma, Large-Cell, Anaplastic Lymphoma, NK-cell Date: 2011-02-25 Interventions: Drug: brentuximab vedotin 1.2- |
Completed |
Study Name: A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Condition: Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Date: 2009-03-19 Interventions: Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion |
Withdrawn |
Study Name: Denileukine Diftitox for Relapsed ALCL Condition: Anaplastic Large-Cell Lymphoma Date: 2008-12-03 Interventions: Drug: Denileukin Diftitox Deni |
Completed |
Study Name: Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma Condition: Hodgkin Lymphoma Anaplastic Large Cell Lymphoma Date: 2008-01-21 Interventions: Biological: XmAb2513 Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, |
Terminated |
Study Name: SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma Date: 2006-08-16 Interventions: Drug: Cyclophosphamide Given I |
Terminated |
Study Name: Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma Recurrent Childhood Date: 2006-07-19 Interventions: Biological: monoclonal antibody SGN-30 |